Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1056/NEJMoa2107051 http://scihub22266oqcxt.onion/10.1056/NEJMoa2107051 34107198!8362588!34107198     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=34107198&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       N+Engl+J+Med 2021 ; 385 (8): 720-728 Nephropedia Template TP {{tp|p=34107198|t=2021. Adjunct Immune Globulin for Vaccine-Induced Immune Thrombotic Thrombocytopenia |pdf=|usr=}}{{34107198}} gab.com Text Adjunct Immune Globulin for Vaccine-Induced Immune Thrombotic Thrombocytopenia JO: N Engl J Med http://www.kidney.de/pget.php?&tw=1&pmid=34107198 #FOAvip The use of high-dose intravenous immune globulin (IVIG) plus anticoagulation is recommended for the treatment of vaccine-induced immune thrombotic thrombocytopenia (VITT), a rare side effect of adenoviral vector vaccines against coronavirus disease 2019 (Covid-19). We describe the response to IVIG therapy in three of the first patients in whom VITT was identified in Canada after the receipt of the ChAdOx1 nCoV-19 vaccine. The patients were between the ages of 63 and 72 years; one was female. At the time of this report, Canada had restricted the use of the ChAdOx1 nCoV-19 vaccine to persons who were 55 years of age or older on the basis of reports that VITT had occurred primarily in younger persons. Two of the patients in our study presented with limb-artery thrombosis; the third had cerebral venous and arterial thrombosis. Variable patterns of serum-induced platelet activation were observed in response to heparin and platelet factor 4 (PF4), indicating the heterogeneity of the manifestations of VITT in serum. After the initiation of IVIG, reduced antibody-induced platelet activation in serum was seen in all three patients. (Funded by the Canadian Institutes of Health Research.). Twit Text FOAVip Adjunct Immune Globulin for Vaccine-Induced Immune Thrombotic Thrombocytopenia ????N Engl J Med http://www.kidney.de/pget.php?&tw=1&pmid=34107198 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=34107198 #FOAvip English Wikipedia <ref>{{Cite pmid|34107198}}</ref> Adjunct Immune Globulin for Vaccine-Induced Immune Thrombotic Thrombocytopenia #MMPMID34107198 Bourguignon A; Arnold DM; Warkentin TE; Smith JW; Pannu T; Shrum JM; Al Maqrashi ZAA; Shroff A; Lessard MC; Blais N; Kelton JG; Nazy I N Engl J Med 2021[Aug]; 385 (8): 720-728 PMID34107198show ga The use of high-dose intravenous immune globulin (IVIG) plus anticoagulation is recommended for the treatment of vaccine-induced immune thrombotic thrombocytopenia (VITT), a rare side effect of adenoviral vector vaccines against coronavirus disease 2019 (Covid-19). We describe the response to IVIG therapy in three of the first patients in whom VITT was identified in Canada after the receipt of the ChAdOx1 nCoV-19 vaccine. The patients were between the ages of 63 and 72 years; one was female. At the time of this report, Canada had restricted the use of the ChAdOx1 nCoV-19 vaccine to persons who were 55 years of age or older on the basis of reports that VITT had occurred primarily in younger persons. Two of the patients in our study presented with limb-artery thrombosis; the third had cerebral venous and arterial thrombosis. Variable patterns of serum-induced platelet activation were observed in response to heparin and platelet factor 4 (PF4), indicating the heterogeneity of the manifestations of VITT in serum. After the initiation of IVIG, reduced antibody-induced platelet activation in serum was seen in all three patients. (Funded by the Canadian Institutes of Health Research.). |*Immunoglobulins, Intravenous[MESH] |Aged[MESH] |COVID-19 Vaccines/*adverse effects[MESH] |ChAdOx1 nCoV-19[MESH] |Female[MESH] |Fibrin Fibrinogen Degradation Products/analysis[MESH] |Fibrinogen/analysis[MESH] |Heparin/pharmacology[MESH] |Humans[MESH] |Male[MESH] |Middle Aged[MESH] |Platelet Count[MESH] |Platelet Factor 4/pharmacology[MESH] |Serotonin/blood[MESH] |Thrombocytopenia/blood/etiology/*therapy[MESH]Adjunct Immune Globulin for Vaccine-Induced Immune Thrombotic Thromboc(epmc).pdf DeepDyve Pubget Overpricing